PharmAla Biotech Holdings Inc. Files Final Base Shelf Prospectus
TORONTO – PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTCQB: MDXXF), a biotechnology pioneer engaging in the research, development, and manufacturing of MDXX class molecules, including its innovative LaNeo™ MDMA, has filed its final short-form base shelf prospectus. This strategic step serves to enhance the Company’s financial flexibility, enabling it to seize potential financing opportunities as market conditions evolve over the next 25 months.
Understanding the Purpose of the Prospectus
By filing this base shelf prospectus, PharmAla intends to offer various financial instruments, including common shares, warrants, units, subscription receipts, debt securities, and other combinations of such securities (collectively, “Securities”). This initiative has been actively filed across all Canadian provinces and territories, ensuring that PharmAla is well-positioned for future growth.
Leveraging Market Conditions
The Company may utilize the prospectus for “at-the-market distribution” strategies, aligning with the prevailing financial regulations. This approach will allow the Securities to be sold on behalf of PharmAla through the Canadian Securities Exchange (CSE) or other established trading markets. However, it is important to note that as of now, no agreements have been reached regarding such distributions.
Future Plans for Securities Issuance
PharmAla has clarified that there are no immediate plans to initiate any securities issuance under this prospectus. If the decision to proceed is made, the specific terms and intended uses of the proceeds will be transparently presented in a prospectus supplement submitted to Canadian securities regulators.
Collaborative Efforts with Radium Capital
In a noteworthy collaboration, PharmAla has signed a term sheet with Radium Capital, which will provide PharmAla Australia with a loan facility intended to harness the anticipated Research and Development Tax Incentive (“RDTI”) refunds. This strategic lending agreement will play a crucial role as PharmAla Australia prepares to initiate operations in Australia.
Securing Development Financing
Although PharmAla Australia has not yet begun its operational activities, the agreement indicates that once qualifying expenses are incurred, Radium Capital will advance up to 80% of the expected RDTI refund as a loan tranche. Each tranche will be secured solely by the respective RDTI refund.
CEO Insights
Nick Kadysh, CEO of PharmAla Biotech, articulates the significance of this collaboration, stating, "The loan facility with Radium presents an opportunity to nurturing our intellectual property without exposing our innovations to securitization risks." He emphasized that advancing clinical trials through PharmAla Australia aligns with their joint venture commercial strategy and promises substantial returns for investors.
Optimizing Financial Structure
The anticipated execution of a Master Finance Agreement (“MFA”) concurrent with the first drawn tranche on the loan facility is expected to enhance available funding to 85% of the expected RDTI refund while also lowering projected interest rates and settlement fees. This move aims to optimize financial outcomes and reduce risks associated with funding.
CFO's Perspective
Will Avery, CFO, echoed similar sentiments, stating, "As we embark on our Clinical Trial work, securing efficient, low-risk debt funding will allow us to maximize our future tax incentives. Partnerships with firms like Radium are critical in driving the cost efficiencies we are targeting in our Australian clinical trials.”
About PharmAla Biotech Holdings Inc.
PharmAla Biotech Holdings Inc. is at the forefront in the field of biotechnology. The Company specializes in the research, development, and manufacturing of MDXX class molecules, notably MDMA. With a dual mission, PharmAla seeks to address the pressing need for clinical-grade MDMA, facilitating clinical trials and commercial sales in various jurisdictions while innovating new therapeutic options in the same class. Presently, PharmAla is the sole provider of clinical-grade MDMA for patient treatments beyond clinical trials.
Innovation and Regulatory Engagement
PharmAla’s R&D unit has achieved remarkable progress, demonstrating proof-of-concept for various intellectual property families, including its lead molecule ALA-002. The organization's commitment to nurturing regulatory relationships underscores its philosophy that genuine success within the psychedelics industry can be realized through collaborative partnerships.
Contact Information
Anyone seeking more information is encouraged to reach out to Nicholas Kadysh, Chief Executive Officer of PharmAla Biotech Holdings Inc. via email at press@PharmAla.ca or by phone at 1-855-444-6362. More comprehensive information can also be found at www.PharmAla.ca.
Frequently Asked Questions
What is the purpose of PharmAla's base shelf prospectus?
The prospectus offers PharmAla the ability to access various financing options during favorable market conditions over a 25-month period.
How does the loan from Radium Capital benefit PharmAla Australia?
The loan provides funding based on projected RDTI refunds, allowing PharmAla Australia to proceed with research without incurring immediate costs.
What is the significance of the anticipated Master Finance Agreement?
This agreement is expected to increase funding availability and reduce costs associated with the loan, optimizing PharmAla's financial strategy.
Who can be contacted for more information regarding PharmAla?
Individuals can contact Nicholas Kadysh, PharmAla's CEO, via email or phone for further inquiries and information.
How is PharmAla positioned in the biotechnology market?
PharmAla is a leader in MDXX class molecule innovation, focusing on developing clinical-grade MDMA and fostering relationships with regulators to support its growth.
